Genetic test for KRAS/NRAS mutations to predict response to EGFR inhibitor therapies.
Specific activating mutations in KRAS and NRAS genes indicate there is likely to be reduced response to EGFR inhibitor therapy. Lack of activating mutations defines eligibility for accessing anti-EGFR therapies under the Pharmaceutical Benefits Scheme (PBS).
Colorectal cancer solid tumour panel
Testing of metastatic colorectal cancer tumour tissue to determine the eligibility for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme (PBS).
KRAS, NRAS, BRAF, PIK3CA, EGFR
NGS Oncomine Precision Assay
1 week from receipt of sample
73338 Criteria apply – dependent on tumour type and stage
If not MBS eligible, please contact 1800 822 999 for pricing details
Standard pathology request form
FFPE Tumour Tissue
6 x 5 micron slides plus 1 x H&E stained slide required
